Table 1 Outcome measures by study visits

Demographic

Interview questionnaire

1,3,5,7,9,11,13

Menstrual cycle:

Interview questionnaire

1,3,5,7,9,11,13

 menstrual dates,

 cycle characteristics

 ovulation test

2,4,6,8,10,12

Menopausal symptoms

Symptom questionnaire⁵

all odd visits 1-27

Daily symptom reports

all odd visits 1-27

 Health: gynecologic,

 reproductive,

 medications,

 health practices/

behaviors

Interview questionnaire

all odd visits 1-27

General

SF-12 Health Survey²⁴

all odd visits 1-27

Physical activity

Questionnaire⁶

4,12,16,20,22,24,25,27

Kaiser Physical Activity Survey³⁷

25,27

Sleep

SMH Sleep Questionnaire^8,9

1,3,5,7,11,13,15,19

WHI Insomnia Rating Scale²⁸

19,21,23,25,27

Apnea Prediction Index²⁹

19,21,23,25,27

Mood and anxiety

PRIME-MD¹⁵

2,4,6,8,10,12

Patient Health Questionnaire^16,17

14,16,18,20,21,23,25 27

CES-Depression Scale^18,19

all odd visits 1-27

Zung Anxiety Scale²⁰

all odd visits 1-27

Perceived Stress (PSS)²¹

2,4,6,8,10,12,

3–27 (odd visits)

Quality of Life

Q-les-Q²²

all odd visits

Utian QOL Scale²³

21,25,27

Sexual function

Female Sexual Function Index³⁰

15,17,19,22,24,26,28

Interview Questionnaire:

Abuse

11,17,19,23

Interest

17,19,21,23,25,27

Libido

all odd visits 1-27

Vaginal

Urinary Tract Rating

(BFLUTS-SF)³⁸

21,24,26,28

Interview Questionnaire

Dryness

odd visits 3-27

Urine leaks

odd visits 3-27

Social support

Interview Questionnaire

1, 9, 15, 19

Social Adjustment Scale³¹

1,3,5,11,13,15,22

Life Events

9,11,13,17,21,24,25,27

Cognition

Cognitive memory tests

all even visits 2-28

Buschke-Fuld Selective

Reminding Test³²

Digit Symbol Substitution³³

Digit Symbol Copy³³

Diet

Dietary Assessment

Questionnaire³⁹

4, 10, 12, 14, 18

Interview Questionnaire

3,5,7,11,15,19-17 (odd)

Anthropomorphic

Measurement:

Height, weight, waist, hip

all odd visits 1-27

Wrist

23,25,27

Hormones

Estradiol, follicle stimulating hormone, Luteinizing hormone, DHEAS, Testosterone, inhibin b

all visits 1-28

Sex hormone binding globulin

all visits 13-28

Anti-mullerian hormone

V1 to various

endpoints

Genotypes

413 participants